The European Union has approved a new hemp variety that’s high in cannabigerol, a compound more commonly known as CBG. CBG is known as the “mother” cannabinoid, the precursor to CBD, CBN, CBC, and THC, and it has applications in everything from beauty and cosmetics to healthcare. In particular, it is most well-known for its anti-inflammatory, antibacterial, and antioxidant properties.
A new variety of hemp has been added to the catalog of the European Union. Its particularity: it was selected for its high content of CBG, which is short for cannabigerol.
How this new CBG variety plays out with adoption across the continent is still unknown, however, we will be following its development, along with other important news here and in our free-to-download cannabis news app.
This High CBG Variety Is Called Enectarol
This new high CBG variety, named Enectarol, was under development for 5 years by the Italian-Dutch company Enecta. The strain produces 5.5% CBG and less than 0.1% THC.
“There is a lack of true hemp flower strains for cannabinoids in Europe, as most varieties in the catalog are spin-offs of fiber strains,” Paolini told HempToday. “New genetics for the industry are evolving at an incredible rate, but the common EU catalog does not reflect this evolution. The lack of new varieties is a sore point for the European hemp industry.”
What is CBG?
CBG (cannabigerol), is one of the 120 cannabinoids found in cannabis. CBG is known as the “mother” cannabinoid, the precursor to CBD, CBN, CBC, and THC.
CBG activates both CB1 and CB2 receptors in the endocannabinoid system, offering the promise that it may hold the joint qualities of all other cannabinoids combined.
Studies have shown that CBG shows promise for conditions such as glaucoma, inflammatory bowel disease, and Huntington’s disease, and can inhibit tumor growth in some cases; it is known to kill or slow down bacteria and promote bone development.
EU Comission Says it Is Safe to Use
Last year, the European Commission added CBG to the EU Cosmetic Ingredients Database (Cosing), indicating that the compound is safe to use in health and beauty products. When applied topically, CBG acts on the CB1 and CB2 endocannabinoid receptors, which are located in the skin.
According to its proponents, this hemp-derived compound has anti-inflammatory, antibacterial, and antioxidant properties that help the endocannabinoid system maintain healthy skin function.
(Featured image by Kindel Media via Pexels)
DISCLAIMER: This article was written by a third-party contributor and does not reflect the opinion of Hemp.im, its management, staff, or its associates. Please review our disclaimer for more information.
This article may include forward-looking statements. These forward-looking statements generally are identified by the words “believe,” “project,” “estimate,” “become,” “plan,” “will,” and similar expressions. These forward-looking statements involve known and unknown risks as well as uncertainties, including those discussed in the following cautionary statements and elsewhere in this article and on this site. Although the Company may believe that its expectations are based on reasonable assumptions, the actual results that the Company may achieve may differ materially from any forward-looking statements, which reflect the opinions of the management of the Company only as of the date hereof. Additionally, please make sure to read these important disclosures.
First published by Newsweed, a third-party contributor translated and adapted the article from the original. In case of discrepancy, the original will prevail.
Although we made reasonable efforts to provide accurate translations, some parts may be incorrect. Hemp.im assumes no responsibility for errors, omissions, or ambiguities in the translations provided on this website. Any person or entity relying on translated content does so at their own risk. Hemp.im is not responsible for losses caused by such reliance on the accuracy or reliability of translated information. If you wish to report an error or inaccuracy in the translation, we encourage you to contact us.
J. Frank Sigerson is a business and financial journalist primarily covering crypto, cannabis, crowdfunding, technology, and marketing. He also writes about the movers and shakers in the stock market, especially in biotech, healthcare, mining, and blockchain. In the past, he has shared his thoughts on IT and design, social media, pop culture, food and wine, TV, film, and music. His works have been published in Investing.com, Equities.com, Seeking Alpha, Mogul, Small Cap Network, CNN, Technology.org, among others.